A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors
一项针对晚期实体瘤患者的首次人体试验、1/2a期、开放标签研究,旨在评估SQ3370(一种首创的基于阿霉素的点击化学疗法)的疗效。
期刊:Neuro-Oncology
影响因子:
doi:10.1101/2025.06.02.25328445
Chawla, S P; Abella, E; Wieland, S; Nguyen, T-H; Srinivasan, S; Alečković, M; Kwatra, V; Subbiah, V; Bui, N; Bhadri, V A; Weiss, M C; Agulnik, M; Ryan, C W; Guminski, A D; Mejía Oneto, J M